SciELO - Scientific Electronic Library Online

 
vol.66 issue1Design and implementation of an electronic program of medical drugs surveillance with online capture in the Children Hospital of Mexico Federico GomezBurkholderia cepacia and chronic granulomatous disease: a case report author indexsubject indexsearch form
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Boletín médico del Hospital Infantil de México

Print version ISSN 1665-1146

Abstract

OLAYA-VARGAS, Alberto et al. Evaluation of treatment with VAMP plus involved-field radiation in Mexican pediatric patients with early-stage Hodgkin lymphoma. Bol. Med. Hosp. Infant. Mex. [online]. 2009, vol.66, n.1, pp.60-67. ISSN 1665-1146.

Introduction. Purpose: To evaluate outcome and assess toxicity of patients with early-stage Hodgkin lymphoma treated with VAMP and low-dose involved-field radiation. Methods. Patients with clinical favorable stages Hodgkin lymphoma were treated with 4 cycles of VAMP (vinblastine 6 mg/m2sc, doxorrubicyn 25 mg/m2sc, methotrexate 20 mg/ m2sc, and prednisone 40 mg/m2sc) administrated on day 1 and day 15. And 21.6 Gy involvedfied radiation. The over-all survival was estimated using Kaplan-Meier and Cox methods. Results. 17 patients were included, the median age was 7 years. Two patients present progressive disease at 4 and 16 months respectively. The overall survival were 94.12% with follow-up of 66 months (IC 95%), the event-free survival were 88.24% with follow up of 63 months (IC 95%). Conclusions. The combined modality therapy with chemotherapy and involved-field radiation (21.6 Gy) shows a better overall survival. The radiation toxicity was elevated, for that reason we must try to reduce the dose of radiotherapy at 15 Gy in patients with complete response to treatment.

Keywords : Hodgkin lymphoma; VAMP; involved-field radiation.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License